{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T07:50:04Z","timestamp":1784188204680,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012091","name":"NIHR Clinical Research Network Thames Valley and South Midlands","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012091","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.vaccine.2024.126167","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T07:35:41Z","timestamp":1721979341000},"page":"126167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Implementation and adherence to regular asymptomatic testing in a COVID-19 vaccine trial"],"prefix":"10.1016","volume":"42","author":[{"given":"Lucy R.","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine R.W.","family":"Emary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodie","family":"Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica P.J.","family":"Larwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maheshi N.","family":"Ramasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C.","family":"Grassly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merryn","family":"Voysey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.vaccine.2024.126167_bb0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002126","article-title":"Challenges in the interpretation of dengue vaccine trial results","volume":"7","author":"Rodriguez-Barraquer","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2024.126167_bb0010","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1080\/14787210.2019.1693259","article-title":"Asymptomatic malaria in the clinical and public health context","volume":"17","author":"Cheaveau","year":"2019","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"34","key":"10.1016\/j.vaccine.2024.126167_bb0015","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2109229118","article-title":"Asymptomatic SARS-CoV-2 infection: a systematic review and meta-analysis","volume":"118","author":"Sah","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2024.126167_bb0020","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/aje\/kwy239","article-title":"Analyzing vaccine trials in epidemics with mild and asymptomatic infection","author":"Kahn","year":"2019","journal-title":"American Journal of Epidemiology"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126167_bb0025","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1074\/mcp.M114.044677","article-title":"RTS,S vaccination is associated with serologic evidence of decreased exposure to Plasmodium falciparum liver- and blood-stage parasites","volume":"14","author":"Campo","year":"2015","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.vaccine.2024.126167_bb0030","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19","author":"Sadoff","year":"2021","journal-title":"New England J Medicine: Massachusetts Medical Society"},{"key":"10.1016\/j.vaccine.2024.126167_bb0035","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S0140-6736(21)00628-0","article-title":"Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012\/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial","author":"Emary","year":"2021","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126167_bb0040","doi-asserted-by":"crossref","first-page":"15531","DOI":"10.1038\/s41598-021-94719-y","article-title":"COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact","volume":"11","author":"Swan","year":"2021","journal-title":"Sci Rep"},{"issue":"19","key":"10.1016\/j.vaccine.2024.126167_bb0045","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1056\/NEJMoa2113017","article-title":"Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase","volume":"385","author":"El Sahly","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.126167_bb0050","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","author":"Polack","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126167_bb0055","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/cid\/ciac803","article-title":"Safety and efficacy of the NVX-CoV2373 coronavirus disease 2019 vaccine at completion of the placebo-controlled phase of a randomized controlled trial","volume":"76","author":"Heath","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"10317","key":"10.1016\/j.vaccine.2024.126167_bb0060","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/S0140-6736(21)02000-6","article-title":"Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial","volume":"398","author":"Ella","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2024.126167_bb0065","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1016\/S1473-3099(20)30773-8","article-title":"What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2","volume":"21","author":"Hodgson","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126167_bb0070","doi-asserted-by":"crossref","first-page":"e764","DOI":"10.1093\/cid\/ciab914","article-title":"Measuring vaccine efficacy against infection and disease in clinical trials: sources and magnitude of Bias in coronavirus disease 2019 (COVID-19) vaccine efficacy estimates","volume":"75","author":"Williams","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126167_bb0075","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0197-2456(98)00042-7","article-title":"Sensitivity, specificity, and vaccine efficacy","author":"Lachenbruch","year":"1998","journal-title":"Controlled Clinical Trials"},{"key":"10.1016\/j.vaccine.2024.126167_bb0080","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2024.126167_bb0085","series-title":"Estimating the effectiveness of routine asymptomatic PCR testing at different frequencies for the detection of SARS-CoV-2 infections","first-page":"106","author":"Hellewell","year":"2021"},{"key":"10.1016\/j.vaccine.2024.126167_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2020.10.003","article-title":"Specificity and positive predictive value of SARS-CoV-2 nucleic acid amplification testing in a low-prevalence setting","volume":"27","author":"Skittrall","year":"2021","journal-title":"Clinical Microbiology and Infection: Elsevier BV"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126167_bb0095","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1017\/ice.2022.40","article-title":"Use of serial testing to interrupt a severe acute respiratory coronavirus virus 2 (SARS-CoV-2) outbreak on a hospital medical floor-Minnesota, October-December 2020","volume":"44","author":"Prabhu","year":"2023","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126167_bb0100","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13014-021-01760-2","article-title":"Implementation, adherence, and results of systematic SARS-CoV-2 testing for asymptomatic patients treated at a tertiary care regional radiation oncology network","volume":"16","author":"Prabhu","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.vaccine.2024.126167_bb0105","article-title":"Application of a serial antigen-based testing strategy for severe acute respiratory syndrome coronavirus 2 and student adherence in a university setting: Wisconsin, October-November 2020. Open forum","volume":"8(10):ofab472","author":"Bigouette","year":"2021","journal-title":"Infect Dis Ther"},{"issue":"46","key":"10.1016\/j.vaccine.2024.126167_bb0110","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.15585\/mmwr.mm6946e1","article-title":"Implementation of a pooled surveillance testing program for asymptomatic SARS-CoV-2 infections on a college campus - Duke University, Durham, North Carolina, august 2-October 11, 2020","volume":"69","author":"Denny","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"10.1016\/j.vaccine.2024.126167_bb0115","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/ije\/dym087","article-title":"Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials","volume":"36","author":"Pildal","year":"2007","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2024.126167_bb0120","article-title":"Adherence to the test, trace, and isolate system in the UK: results from 37 nationally representative surveys","volume":"372","author":"Smith","year":"2021","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126167_bb0125","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/jech-2021-216876","article-title":"Patterns of compliance with COVID-19 preventive behaviours: a latent class analysis of 20 000 UK adults","volume":"76","author":"Wright","year":"2022","journal-title":"J Epidemiol Community Health"},{"key":"10.1016\/j.vaccine.2024.126167_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.physrep.2021.02.001","article-title":"Non-pharmaceutical interventions during the COVID-19 pandemic: a review","volume":"913","author":"Perra","year":"2021","journal-title":"Phys Rep"},{"issue":"44","key":"10.1016\/j.vaccine.2024.126167_bb0135","doi-asserted-by":"crossref","first-page":"27285","DOI":"10.1073\/pnas.2012520117","article-title":"Gender differences in COVID-19 attitudes and behavior: panel evidence from eight countries","volume":"117","author":"Galasso","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126167_bb0140","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.7861\/clinmed.2020-0839","article-title":"The impact of false positive COVID-19 results in an area of low prevalence","volume":"21","author":"Healy","year":"2021","journal-title":"Clin Med (Lond)"},{"issue":"8","key":"10.1016\/j.vaccine.2024.126167_bb0145","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1056\/NEJMoa2116597","article-title":"Effect of Covid-19 vaccination on transmission of alpha and Delta variants","volume":"386","author":"Eyre","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24008302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24008302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T01:38:56Z","timestamp":1728524336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24008302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":29,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0264410X24008302"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126167","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.02.28.24303505","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implementation and adherence to regular asymptomatic testing in a COVID-19 vaccine trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126167","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126167"}}